Announcements Trials

Browse Landscape Eligibility

Clinical Trials

0 trials

Recent Start date Enrollment

HER2+ Breast Cancer × Ado-Trastuzumab Emtansine × 1 year × Clear all

Sponsor

Conditions

Breast Neoplasms 24 Neoplasm Metastasis 4 Neoplasms 3 Salivary Gland Neoplasms 2 HER2-positive Breast Cancer 2 Carcinoma, Non-Small-Cell Lung 2 Uterine Cervical Neoplasms 1 Urologic Neoplasms 1 Urinary Bladder Neoplasms 1 Unrespectable Locally Advanced and or Metastatic HER2 Positive Breast Cancer Participants 1 Triple Negative Breast Neoplasms 1 Stomach Neoplasms 1 Solid Tumors 1 Patient Preference 1 Pathologic Complete Response 1 Ovarian Neoplasms 1 Neoplasm, Residual 1 Multiple Myeloma 1 Lymphoma 1 Lung Neoplasms 1 Inflammatory Breast Neoplasms 1 Hematologic Neoplasms 1 Hemangiosarcoma 1 Heart Failure 1 HER2-positive Metastatic Breast Cancer 1 HER2-Positive Primary Breast Cancer Participants With Residual Invasive Disease Following Neoadjuvant Therapy 1 HER2-Positive Primary Breast Cancer 1 Genomic Instability 1 Endometrial Neoplasms 1 Colorectal Neoplasms 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

No trials found.

Data powered by HemOnc (CC BY 4.0) Colophon ⚡